| __timestamp | Travere Therapeutics, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 47795223 | 15411924 |
| Thursday, January 1, 2015 | 50426000 | 22593274 |
| Friday, January 1, 2016 | 70853000 | 33173050 |
| Sunday, January 1, 2017 | 78168000 | 62224159 |
| Monday, January 1, 2018 | 123757000 | 95607434 |
| Tuesday, January 1, 2019 | 140963000 | 221269028 |
| Wednesday, January 1, 2020 | 131773000 | 400745069 |
| Friday, January 1, 2021 | 210328000 | 580520000 |
| Saturday, January 1, 2022 | 235780000 | 663366000 |
| Sunday, January 1, 2023 | 244990000 | 755113687 |
Data in motion
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, argenx SE and Travere Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.
Since 2014, argenx SE has shown a remarkable increase in R&D spending, growing by an impressive 4,800% by 2023. This surge underscores their aggressive pursuit of groundbreaking therapies. In contrast, Travere Therapeutics, Inc. has seen a more modest growth of approximately 410% over the same period.
By 2023, argenx SE's R&D expenses were nearly three times those of Travere Therapeutics, Inc., highlighting their strategic focus on expanding their research capabilities. This trend suggests a potential shift in market leadership as argenx SE continues to invest heavily in its future.
Eli Lilly and Company or Travere Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Sanofi and Travere Therapeutics, Inc.
argenx SE vs Arrowhead Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: argenx SE vs Wave Life Sciences Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and Travere Therapeutics, Inc.
R&D Insights: How Corcept Therapeutics Incorporated and Travere Therapeutics, Inc. Allocate Funds
R&D Insights: How Alpine Immune Sciences, Inc. and Travere Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Amicus Therapeutics, Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc.